Alphamab Oncology

English 中文简体中文繁体

Alphamab Oncology will present updated data on innovative bispecific antibody combination therapy at ASCO 2023

Efficacy and Safety of KN026 in combination with KN046 in Patients with Locally Advanced Unresectable or Metastatic HER2-positive Other Solid Tumors
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE

We will further explore the efficacy and safety of KN026 in combination with docetaxel through this registered clinical trial, in the hope of bringing more effective treatment options to patients with HER2-positive breast cancer
Late-Breaking Research! Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023

KN052 has acceptable pharmacokinetics and safety, and its antitumor activity is significantly stronger than that of the two single-target control antibodies used alone and in combination

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : To become a fully integrated global leading biopharmaceutical company

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Proprietary Platforms
Innovative Pipeline
Biologics Manufacturing

WORLD-CLASS BISPECIFIC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. At Alphamab Oncology, we have developed two proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

Learn More

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

Learn More

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Learn More

Company

Overview

Board of Directors

Partnering

Core competence

Technology

Bispecific

Mix-mAb

Biologics Manufacturing

Publications

Pipeline

Overview

Envafolimab(KN035)

KN046

KN026

KN026+KN046

KN019

KN052

JSKN003

Investors

Information Disclosure

Corporate Governance

Stock Information

IR Contacts

Email Subscription

News

Press Release

Media Report

Career

Corporate Culture

Job Opportunities

Contact Us

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : To become a fully integrated global leading biopharmaceutical company

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

WORLD-CLASS BISPECIFIC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. At Alphamab Oncology, we have developed two proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable Our Vision : To become a fully integrated global leading biopharmaceutical company Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

WORLD-CLASS BISPECIFIC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. At Alphamab Oncology, we have developed two proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Our Mission : To make cancer manageable and curable

Our Vision : To become a fully integrated global leading biopharmaceutical company

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth